Promising New Treatment combinations with Epcoritamab Show Durable Remissions in diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma. Recent research presented at the American Society of hematology (ASH) 2025 conference highlights notable advancements in treatment, specifically focusing on the use of epcoritamab in combination with chemotherapy regimens. These findings offer hope for improved outcomes, especially for patients with high-risk disease and those who are older or less fit for intensive treatment. HearS a detailed look at the latest data.
Epcoritamab + R-mini-CHOP: A Strategy for Older or Frail Patients
One study (EPCORE NHL-2 trial, Poster 64) investigated a fixed-duration regimen of epcoritamab, a novel bispecific antibody, combined with reduced-intensity chemotherapy (R-mini-CHOP). This approach aims to maximize efficacy while minimizing toxicity in patients who may not tolerate standard, more aggressive treatments.
Key Findings:
* Patient Population: 28 patients with a median age of 81 years participated in the study.
* High Response Rates: An remarkable 89% overall response rate (ORR) was observed, with a complete response (CR) rate of 86%.
* Durable Remissions: The median duration of response and complete response haven’t been reached yet, suggesting long-lasting benefits.
* Long-Term Survival: Estimated 2-year progression-free survival (PFS) was 76%, and overall survival (OS) reached 82%.
* Deep Remissions: Remarkably, 95% of evaluable patients achieved minimal residual disease (MRD) negativity, a strong indicator of treatment success. This was consistent even in patients with high-risk features like IPI scores of 3-5 and bulky disease.
* Treatment Completion & Tolerability: Most patients (79%) completed treatment, and the median R-mini-CHOP dose intensity was high (94% or greater). While grade 3 or greater infections occured in 29% of patients, only 11% discontinued epcoritamab due to adverse events.
This combination demonstrates a compelling benefit for older patients, allowing them to complete treatment and achieve deep, durable remissions with manageable side effects.
Epcoritamab + R-CHOP Followed by Monotherapy: A Powerful Approach for High-Risk DLBCL
A second analysis (EPCORE NHL-2 trial, Poster 1955) explored a different strategy: combining epcoritamab with standard R-CHOP chemotherapy for six cycles, followed by epcoritamab monotherapy for up to a year. this approach is designed for patients with high International prognostic Index (IPI) scores (3-5), indicating a more aggressive disease course.
Key Findings:
* Patient Population: 47 patients with a median age of 64 years were enrolled, with a significant proportion having high IPI scores (57% with IPI 3, 38% with IPI 4-5).
* Exceptional Response rates: The ORR was an outstanding 98%, with a CR rate of 85%.
* Sustained Remissions: 67% of responses and 75% of CRs were ongoing at 33 months, indicating durable disease control.
* Consistent Results Across Subgroups: High CR rates were observed regardless of IPI score, age, tumor size, or cell of origin.
* Deep MRD Negativity: 86% of MRD-evaluable patients were MRD negative by cycle 3 day 1, with sustained reductions in circulating tumor DNA (ctDNA) through cycle 6 day 1.
* treatment Completion & Long-Term Follow-Up: 94% of patients completed all six cycles of R-CHOP, and 68% completed the entire treatment plan. Among those who completed treatment, 87% maintained their response at a median follow-up of 25.3 months.
* Manageable Safety profile: The safety profile was consistent with previous reports, with serious infections primarily occurring in the first